Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

EMA recommends extension of therapeutic indications for sacituzumab govitecan
Дата публикации: 18-09-2026 07:09:00

New indication concerns a combination with pembrolizumab, for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan0510-07-2026
2EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin0519-06-2026
3EMA recommends extension of therapeutic indications for teclistamab08.3611-09-2026
4EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan0526-06-2026
5Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk Breast Cancer018.8530-07-2026
6FDA Approves Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)017.0225-06-2026
7Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer01028-07-2026
8Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer08.6401-08-2026
9Гинцбург допустил расширение показаний для применения онкопрепарата "Арейма"08.6220-08-2026
10أدوية جديدة تحل محل العلاج الكيميائي لسرطان الثدي العدواني5725-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 11.1. Источник: www.esmo.org.